China Pharma H1 2022 Financials: 40% of Firms Report Revenue and Profit Growth
A total of 449 pharmaceutical and health-tech companies listed in China have released their H1...
Shanghai Pharmaceuticals
Shanghai Pharma’s CD20 Antibody Advances to Primary Nephropathy Trial After NMPA Approval
China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products...
Shanghai Pharmaceuticals Gets NMPA Approval for B013 in Triple-Negative Breast Cancer
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products Administration...
CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...
Shanghai Pharmaceuticals Partners with HKSTP and Shanghai Biomedicine Fund on R&D Collaboration
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a...
Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China
China-based pharmaceutical giant Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) announced a licensing agreement with compatriot...